- 作者：Charles M Fogarty ; Patricia Buchanan ; Michel Aubier ; Malik Baz ; Dirkie van Rensburg ; Manickam Rangaraju ; Roomi Nusrat
- 关键词：Bacteriologic efficacy ; Clinical efficacy ; Ketolide ; Streptococcus pneumoniae ; Telithromycin
- 刊名：International Journal of Infectious Diseases
- 出版年：2006
- 出版时间：March 2006
- 年：2006
- 卷：10
- 期：2
- 页码：136-147
- 全文大小：362 K
Methods
Data were examined from 5534 adult/adolescent patients with community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), or acute bacterial sinusitis, who had received telithromycin for 5–10 days or a comparator antibacterial.
Results
Streptococcus pneumoniae was identified in 704/2060 (34.2 % ) bacteriologically evaluable patients. The respective per-protocol clinical cure rates for telithromycin and comparators were 94.3 % and 90.0 % (CAP); 81.5 % and 78.9 % (AECB); 90.1 % and 87.5 % (acute sinusitis); 92.7 % and 87.6 % (all indications). Clinical cure rates were 28/34 (82.4 % ) and 5/7, respectively, for penicillin-resistant infections, and 44/52 (84.6 % ) and 11/14, respectively, for erythromycin-resistant infections. Of 82 patients with pneumococcal bacteremia, 74 (90.2 % ) were clinically cured after telithromycin treatment, including 5/7 and 8/10 with penicillin- or erythromycin-resistant strains, respectively. Adverse events considered possibly related to study medication were reported by 1071/4045 (26.5 % ) telithromycin and 505/1715 (29.4 % ) comparator recipients. These events were generally of mild/moderate severity, and mainly gastrointestinal in nature.
Conclusions
As S. pneumoniae is the leading bacterial cause of community-acquired RTIs, and antibacterial resistance is increasing among this species, these findings support the use of telithromycin as first-line therapy in this setting.